论文部分内容阅读
目的通过测定喉癌患者血清可溶性肿瘤坏死因子受体(sTNFR)水平的变化,探讨其在喉癌诊断和监控中的临床意义。方法应用双抗体夹心酶联免疫吸附测定(ABC-ELISA)检测42例喉癌患者和40例健康成人的血清sTNFRI、sTNFRⅡ的水平,进行比较。结果喉癌患者的血清sTNFR I水平(1 463.34±669.07)pg/mL与健康对照组(549.30±293.29)pg/mL比较差异有统计学意义(P<0.05),而sTNFRⅡ的水平与健康对照组比较差异无统计学意义(P>0.05);sTNFRⅠ及sTNFRⅡ水平在喉癌组各型间差异均无统计学意义(P>0.05),sTNFRⅠ水平在喉癌各期间差异有统计学意义(P<0.05);而sTNFRⅡ水平在喉癌各期间差异无统计学意义(P>0.05)。有淋巴结转移喉癌患者sTNFRⅠ水平显著高于无淋巴结转移的喉癌患者(P<0.05);而sTNFRⅡ水平在有淋巴结转移和无淋巴结转移的患者间差异无统计学意义(P>0.05)。结论 sTNFRⅠ的检测对喉癌的早期诊断和预后评估具有实用价值。
Objective To investigate the clinical significance of serum soluble tumor necrosis factor receptor (sTNFR) in patients with laryngeal cancer and to evaluate its clinical significance in the diagnosis and surveillance of laryngeal cancer. Methods Serum levels of sTNFRI and sTNFR Ⅱ were detected in 42 patients with laryngeal cancer and 40 healthy adults by double antibody sandwich enzyme-linked immunosorbent assay (ABC-ELISA). Results The serum sTNFR I level in patients with laryngeal cancer was significantly lower than that in healthy controls (1463 ± 449.07 pg / mL vs 549.30 ± 293.29 pg / mL, P <0.05), while the level of sTNFRII was significantly lower than that in healthy controls There was no significant difference between the two groups (P> 0.05). The levels of sTNFRⅠ and sTNFRⅡ in laryngocarcinoma group had no statistical significance (P> 0.05) 0.05). There was no significant difference in sTNFRⅡlevel between laryngeal squamous cell carcinoma (P> 0.05). The level of sTNFRI in patients with lymph node metastasis was significantly higher than that in patients with laryngeal cancer without lymph node metastasis (P <0.05). There was no significant difference in the level of sTNFRⅡ between patients with lymph node metastasis and without lymph node metastasis (P> 0.05). Conclusion The detection of sTNFR Ⅰ has practical value in the early diagnosis and prognosis evaluation of laryngeal cancer.